MicroRNAs as Candidate Biomarkers for Alzheimer’s Disease

The neurological damage of Alzheimer’s disease (AD) is thought to be irreversible upon onset of dementia-like symptoms, as it takes years to decades for occult pathologic changes to become symptomatic. It is thus necessary to identify individuals at risk for the development of the disease before sym...

Full description

Bibliographic Details
Main Authors: Colin Kanach, Jan K. Blusztajn, Andre Fischer, Ivana Delalle
Format: Article
Language:English
Published: MDPI AG 2021-02-01
Series:Non-Coding RNA
Subjects:
MCI
Online Access:https://www.mdpi.com/2311-553X/7/1/8
id doaj-6c8e4056c1a14a139ce213a19696ff99
record_format Article
spelling doaj-6c8e4056c1a14a139ce213a19696ff992021-02-02T00:03:30ZengMDPI AGNon-Coding RNA2311-553X2021-02-0178810.3390/ncrna7010008MicroRNAs as Candidate Biomarkers for Alzheimer’s DiseaseColin Kanach0Jan K. Blusztajn1Andre Fischer2Ivana Delalle3Department of Pathology and Laboratory Medicine, Rhode Island Hospital, Lifespan Academic Medical Center, The Warren Alpert Medical School of Brown University, Providence, RI 02903, USADepartment of Pathology and Laboratory Medicine, Boston University School of Medicine, 670 Albany Street, Boston, MA 02118, USAGerman Center for Neurodegenerative Diseases, Department for Epigenetics and Systems Medicine in Neurodegenerative Diseases, 37075 Göttingen, GermanyDepartment of Pathology and Laboratory Medicine, Rhode Island Hospital, Lifespan Academic Medical Center, The Warren Alpert Medical School of Brown University, Providence, RI 02903, USAThe neurological damage of Alzheimer’s disease (AD) is thought to be irreversible upon onset of dementia-like symptoms, as it takes years to decades for occult pathologic changes to become symptomatic. It is thus necessary to identify individuals at risk for the development of the disease before symptoms manifest in order to provide early intervention. Surrogate markers are critical for early disease detection, stratification of patients in clinical trials, prediction of disease progression, evaluation of response to treatment, and also insight into pathomechanisms. Here, we review the evidence for a number of microRNAs that may serve as biomarkers with possible mechanistic insights into the AD pathophysiologic processes, years before the clinical manifestation of the disease.https://www.mdpi.com/2311-553X/7/1/8plasma microRNAomeMCIepigenetic dysregulation
collection DOAJ
language English
format Article
sources DOAJ
author Colin Kanach
Jan K. Blusztajn
Andre Fischer
Ivana Delalle
spellingShingle Colin Kanach
Jan K. Blusztajn
Andre Fischer
Ivana Delalle
MicroRNAs as Candidate Biomarkers for Alzheimer’s Disease
Non-Coding RNA
plasma microRNAome
MCI
epigenetic dysregulation
author_facet Colin Kanach
Jan K. Blusztajn
Andre Fischer
Ivana Delalle
author_sort Colin Kanach
title MicroRNAs as Candidate Biomarkers for Alzheimer’s Disease
title_short MicroRNAs as Candidate Biomarkers for Alzheimer’s Disease
title_full MicroRNAs as Candidate Biomarkers for Alzheimer’s Disease
title_fullStr MicroRNAs as Candidate Biomarkers for Alzheimer’s Disease
title_full_unstemmed MicroRNAs as Candidate Biomarkers for Alzheimer’s Disease
title_sort micrornas as candidate biomarkers for alzheimer’s disease
publisher MDPI AG
series Non-Coding RNA
issn 2311-553X
publishDate 2021-02-01
description The neurological damage of Alzheimer’s disease (AD) is thought to be irreversible upon onset of dementia-like symptoms, as it takes years to decades for occult pathologic changes to become symptomatic. It is thus necessary to identify individuals at risk for the development of the disease before symptoms manifest in order to provide early intervention. Surrogate markers are critical for early disease detection, stratification of patients in clinical trials, prediction of disease progression, evaluation of response to treatment, and also insight into pathomechanisms. Here, we review the evidence for a number of microRNAs that may serve as biomarkers with possible mechanistic insights into the AD pathophysiologic processes, years before the clinical manifestation of the disease.
topic plasma microRNAome
MCI
epigenetic dysregulation
url https://www.mdpi.com/2311-553X/7/1/8
work_keys_str_mv AT colinkanach micrornasascandidatebiomarkersforalzheimersdisease
AT jankblusztajn micrornasascandidatebiomarkersforalzheimersdisease
AT andrefischer micrornasascandidatebiomarkersforalzheimersdisease
AT ivanadelalle micrornasascandidatebiomarkersforalzheimersdisease
_version_ 1724314713034063872